QCZ484 + Placebo

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mild Hypertension

Conditions

Mild Hypertension

Trial Timeline

Mar 8, 2023 → Jul 1, 2025

NCT ID

NCT06905327

About QCZ484 + Placebo

QCZ484 + Placebo is a phase 1 stage product being developed by Novartis for Mild Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT06905327. Target conditions include Mild Hypertension.

What happened to similar drugs?

8 of 17 similar drugs in Mild Hypertension were approved

Approved (8) Terminated (2) Active (8)

✅Aricept (donepezil hydrochloride) + placeboEisaiApproved

✅Donepezil HClEisaiApproved

✅ElagolixAbbVieApproved

✅Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved

✅Aliskiren + Hydrochlorothiazide + AmlodipineNovartisApproved

✅Rivastigmine PatchNovartisApproved

✅ElidelBayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06905327	Phase 1	Completed	Mar 8, 2023	Jul 1, 2025	Mild Hypertension

Competing Products

20 competing products in Mild Hypertension

See all competitors

Product	Company	Stage	Hype Score
Neurosteroid enantiomer	Oragenics	Phase 2	32
Ranirestat + Placebo	Eisai	Phase 2/3	38
Aricept (donepezil hydrochloride) + placebo	Eisai	Approved	43
Donepezil HCl	Eisai	Approved	43
Donanemab + Aducanumab	Eli Lilly	Phase 3	40
PPAR alpha + Hydrochlorothiazide + Placebo	Eli Lilly	Phase 2	35
Elagolix	AbbVie	Approved	35
AZD1446 + Placebo	AstraZeneca	Phase 2	35
MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection	AstraZeneca	Phase 1	29
Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg	AstraZeneca	Approved	43
AZD5213 + AZD5213 + AZD5213	AstraZeneca	Phase 2	35
budesonide/formoterol (Symbicort)	AstraZeneca	Phase 3	40
MK-8931	Merck	Phase 1	29
Montelukast to placebo + Placebo to montelukast	Merck	Pre-clinical	26
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)	Merck	Phase 3	32
Aliskiren + Hydrochlorothiazide + Amlodipine	Novartis	Approved	43
LCZ696 + Sildenafil	Novartis	Phase 2	35
Rivastigmine Patch	Novartis	Approved	43
AFQ056	Novartis	Phase 1	29
Canakinumab	Novartis	Phase 2	27